The two animal models we established can be used to further study the role of Codanin-1 in erythropoiesis and in the pathogenesis of CDA type I. In particular, the zebrafish model is suitable to perform high-throughput drug screening (Zon and Peterson, 2005; Uechi and Kenmochi, 2019) and will help to identify new therapeutic strategies for individuals with CDA-I. This evidence concerns the gene CDAN1 and congenital dyserythropoietic anemia type 1.